3 results
Approved WMOCompleted
This study will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GDC-0134 in patients with amyotrophic lateral sclerosis (ALS).The long term safety and tolerability of up to 48 weeks of GDC-0134 will…
Approved WMOCompleted
To validate 18F-Flutemetamol PET in the evaluation of plaque vulnerability.
Approved WMOCompleted
The objective is to compare the intervention to standardized care PFMT in terms of clinical, economic and satisfaction outcomes. A secondary objective is to develop a prediction model to identify suitable patients who will benefit the most from the…